Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from Covid-19 booster shots.
The vaccine makers say evidence of waning antibody levels in vaccinated people after six months, as well as an increasing rate of breakthrough infections in countries hit by the Delta variant, support the need for booster shots.
As a result, it is far from clear how many people will need boosters, and how often. The profit potential of booster shots may be limited by the number of competitors who enter the market. Some scientists question whether there is enough evidence that boosters are needed, particularly for younger, healthy people. The World Health Organisation has asked governments to hold off on booster shots until more people worldwide receive their initial doses.
Pfizer declined to comment for the story. During the company’s second-quarter earnings call, executives said they believe a third dose will be necessary six to eight months after vaccination, and regularly afterward.If regular Covid-19 boosters are needed among the general population, the market would most resemble the flu shot business, which distributes more than 600-million doses per year.
Flu shots cost about $18 to $25 a dose, according to US government data and competition has kept price increases in check, with producers raising prices 4 or 5% in 2021.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, Moderna expected to reap billions from Covid vaccine booster marketDrugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come.
Read more »
Pfizer, Moderna to reap billions from Covid-19 vaccine booster marketFor several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.
Read more »
Joe Phaahla urged to get backup vaccines for Pfizer and J&JEffort must be made to secure AstraZeneca and Sinovac Biotech vaccines in the event of a potential shortage of the Pfizer and J&J doses
Read more »
Pfizer, Moderna to reap billions from Covid-19 vaccine booster marketFor several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.
Read more »
Pfizer, Moderna expected to reap billions from Covid vaccine booster marketDrugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come.
Read more »
Vaccinated people urged to report all severe side-effectsThat was the plea on Friday from Prof Hannelie Meyer, the head of the SA Vaccination and Immunisation Centre (Savic) at Sefako Makgatho Health Sciences University in Pretoria.
Read more »